ImmunoCellular Therapeutics announces third quarter 2017 financial results
ImmunoCellular Therapeutics reported net loss for the 2017 third quarter was $3.9 million versus $4.8 million in the same period in 2016. During the nine months ended Sep. 30, 2017, the Company used $11.7 million of cash in operations versus $16.1 million in the same 2016. November 21, 2017